Hospital
Asante Three Rivers Medical Center, LLC
Asante Three Rivers Medical Center, LLC was paid $27.57M by Medicaid between Jan 2018 and Nov 2024, across 145 billing codes. Its largest line is 99284, emergency room visit (serious) — 37% of everything it billed.
33Billing provider infoASANTE THREE RIVERS MEDICAL CENTER, LLC
GRANTS PASS, OR 97527
GRANTS PASS, OR 97527
33aNPI1801891809assigned 06/16/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$27.57M
24GClaims576,307
24DCodes billed145
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Oregon
Rank by total paid#5 of 17
Median peer was paid$13.35M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 78,433 | $2.95M | |
| 2019 | 83,023 | $3.13M | |
| 2020 | 63,525 | $2.97M | |
| 2021 | 82,975 | $3.89M | |
| 2022 | 94,083 | $4.48M | |
| 2023 | 96,049 | $5.16M | |
| 2024incomplete | 78,219 | $4.99M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 37% | 52,249 | 44,616 | $10.33M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 51,601 | 44,051 | $6.74M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 12,298 | 10,920 | $3.06M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 8.7% | 31,166 | 25,646 | $2.41M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.5% | 13,004 | 11,711 | $1.53M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.2% | 11,830 | 10,957 | $609K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 3,942 | 3,659 | $351K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 6,876 | 6,315 | $313K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 5,266 | 4,867 | $258K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,310 | 5,730 | $256K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,413 | 1,346 | $167K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 793 | 345 | $146K |
133 more codes
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,308 | $131K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,923 | $110K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 469 | $85K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,403 | $75K |
| 36415 | Collection of venous blood by venipuncture | <1% | 85,581 | $74K |
| 87800 | <1% | 2,238 | $66K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,373 | $61K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,356 | $60K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,303 | $60K |
| 80053 | Comprehensive metabolic panel | <1% | 68,908 | $56K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,486 | $55K |
| 86900 | <1% | 771 | $55K | |
| 86850 | <1% | 3,052 | $41K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,582 | $41K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 75,594 | $40K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,789 | $36K |
| 86780 | <1% | 3,193 | $28K | |
| 80061 | Lipid panel | <1% | 3,142 | $23K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 184 | $22K |
| 97597 | <1% | 338 | $22K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 571 | $22K |
| 0240U | <1% | 212 | $20K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 609 | $19K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,226 | $17K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 902 | $17K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 223 | $13K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,667 | $13K |
| 87081 | <1% | 3,483 | $13K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,305 | $12K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 349 | $12K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 269 | $8K |
| 84439 | <1% | 1,436 | $7K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 851 | $7K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 55 | $7K |
| 82652 | <1% | 288 | $6K | |
| 99201 | <1% | 54 | $6K | |
| 0450 | Emergency room services | <1% | 144 | $6K |
| 73630 | <1% | 141 | $4K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 132 | $4K |
| 73221 | <1% | 24 | $4K | |
| 80074 | <1% | 93 | $4K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 12 | $3K |
| 87150 | <1% | 128 | $3K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,468 | $2K |
| 82950 | <1% | 606 | $2K | |
| 85027 | <1% | 535 | $2K | |
| 84480 | <1% | 223 | $2K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 17 | $2K |
| 81003 | <1% | 6,320 | $2K | |
| 86803 | <1% | 442 | $2K | |
| 87631 | <1% | 133 | $1K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 269 | $1K |
| 87340 | <1% | 518 | $1K | |
| 87077 | <1% | 500 | $1K | |
| 84702 | <1% | 110 | $1K | |
| 99070 | <1% | 76 | $959.66 | |
| 82043 | <1% | 296 | $881.22 | |
| 81001 | <1% | 19,403 | $856.94 | |
| J3490 | Unclassified drugs | <1% | 71 | $845.87 |
| 82570 | <1% | 312 | $841.62 | |
| 73610 | <1% | 13 | $831.60 | |
| 85610 | <1% | 3,798 | $817.29 | |
| 97162 | <1% | 16 | $776.28 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,863 | $753.64 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 522 | $748.97 |
| 86705 | <1% | 92 | $638.40 | |
| 83690 | <1% | 9,102 | $634.78 | |
| 86762 | <1% | 401 | $609.93 | |
| 82607 | <1% | 54 | $550.26 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 18 | $532.62 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 99 | $482.81 |
| 87641 | <1% | 31 | $364.91 | |
| 87640 | <1% | 31 | $364.91 | |
| 83615 | <1% | 474 | $342.87 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 13 | $333.33 |
| 87070 | <1% | 127 | $331.20 | |
| 87186 | <1% | 122 | $295.84 | |
| 87581 | <1% | 12 | $277.19 | |
| 87486 | <1% | 12 | $277.19 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 88 | $256.50 |
| 84146 | <1% | 15 | $231.00 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,321 | $219.97 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,146 | $170.76 |
| 87205 | <1% | 127 | $164.16 | |
| 85730 | <1% | 726 | $137.10 | |
| 84481 | <1% | 12 | $135.50 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,029 | $99.11 |
| 85007 | <1% | 56 | $92.53 | |
| 84484 | <1% | 4,134 | $76.19 | |
| 80069 | <1% | 15 | $64.15 | |
| 86901 | <1% | 759 | $30.24 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 805 | $25.62 |
| 83605 | <1% | 844 | $24.06 | |
| 80164 | <1% | 12 | $23.24 | |
| 81025 | <1% | 1,677 | $21.35 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 51 | $10.36 |
| 83735 | <1% | 878 | $4.82 | |
| 82962 | <1% | 91 | $2.62 | |
| 80179 | 0% | 12 | $0.00 | |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | 0% | 196 | $0.00 |
| A6446 | Conforming bandage, non-elastic, knitted/woven, sterile, width greater than or equal to three inches and less than five inches, per yard | 0% | 22 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 93 | $0.00 |
| A6196 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size 16 sq. in. or less, each dressing | 0% | 103 | $0.00 |
| 90715 | 0% | 12 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 13 | $0.00 |
| 87634 | 0% | 53 | $0.00 | |
| 82805 | 0% | 13 | $0.00 | |
| 84100 | 0% | 12 | $0.00 | |
| 80143 | 0% | 12 | $0.00 | |
| 87040 | 0% | 24 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 517 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 331 | $0.00 |
| 83880 | 0% | 56 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 759 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 15 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 229 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 25 | $0.00 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 46 | $0.00 |
| 86140 | 0% | 72 | $0.00 | |
| G0378 | Hospital observation service, per hour | 0% | 128 | $0.00 |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | 0% | 82 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 91 | $0.00 |
| 94761 | 0% | 142 | $0.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 133 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 52 | $0.00 |
| 94760 | 0% | 15 | $0.00 | |
| 84703 | 0% | 57 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 13 | $0.00 |
| 85379 | 0% | 15 | $0.00 | |
| A6252 | Specialty absorptive dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | 0% | 32 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 44 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 62 | $0.00 |
| A6197 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROWENHORST, HEATHER (CHIEF FINANCE OFFICER)
Parent organizationASANTE
| Provider | Location | Paid |
|---|---|---|
| Asante | Medford, OR | $29.67M |
| Asante Ashland Community Hospital, LLC | Ashland, OR | $8.99M |
| Asante | Medford, OR | $5.34M |
| Asante Three Rivers Medical Center LLC | Grants Pass, OR | $5.17M |
| Asante Community Services LLC | Medford, OR | $938K |
| Asante Three Rivers Medical Center, LLC | Grants Pass, OR | $64K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.